Forskning ved Københavns Universitet - Københavns Universitet

Forside

Behandling ved tidlig Hodgkin's sygdom

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

In early stage Hodgkin's disease the optimal choice of treatment is still an unresolved issue. Twenty-two randomized trials of radiotherapy alone versus radiotherapy plus combination chemotherapy have been carried out world-wide. The preliminary results of a global meta-analysis of these trials indicate that we still do not definitively know whether or not the early addition of prophylactic chemotherapy improves survival. Arguments in favour of early chemotherapy are: that laparotomy may be avoided, that radiation fields and doses may perhaps be reduced, and that the stress of experiencing a relapse is avoided in many patients. The major argument against early chemotherapy is: that by careful staging and selection of patients and by careful radiotherapy techniques the number of patients exposed to potentially toxic chemotherapy may be kept at a minimum. Recently, trials have been carried out testing chemotherapy alone, results are, however, conflicting. In order not to jeopardize the good results achieved with the standard treatments developed over the last three decades, newer treatment approaches should be carefully tested in large randomized trials before being implemented for general clinical use.
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind155
Udgave nummer46
Sider (fra-til)3750-4
Antal sider5
ISSN0041-5782
StatusUdgivet - 15 nov. 1993

ID: 34086376